M Taboada
3 Papers
M Taboada is an academic researcher. The author has contributed to research in topics: Internal medicine & Hazard ratio. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.
Charles E. Geyer,Judy Garber,R. D. Gelber,Greg Yothers,M Taboada,Louetta A. Ross,PS Rastogi,Karen Y. Cui,Amal Arahmani,Gursel Aktan,A. Armstrong,Monica Arnedos,Judith Balmaña,Joop P. W. van den Bergh,J. Bliss,S. Delaloge,S. Domchek,Andrea Eisen,F. Elsafy,Luis Fein,Anitra Fielding,James M. Ford,S. Friedman,Karen A. Gelmon,L. Gianni,Michael Gnant,Simon J. Hollingsworth,Sa Im,Agnes Jager,Oskar T. Johannsson,Sunil R. Lakhani,Wolfgang Janni,Barbro Linderholm,T-W. Liu,Niklas Loman,Larissa A. Korde,S. Loibl,P. Lucas,Frederik Marmé,Eduardo Martínez de Dueñas,Robin McConnell,Kelly-Anne Phillips,Martine Piccart,Giovanna Rossi,R. K. Schmutzler,Elżbieta Senkus,Z Shao,Paramananda Dash Sharma,C. Singer,Tanja Spanic,Elmar Stickeler,Masakazu Toi,TA Traina,Giuseppe Viale,Gabriele Zoppoli,Y. Park,Rinat Yerushalmi,H Yang,Dan-mei Pang,KH Jung,A. Mailliez,Zusen Fan,Isabelle Tennevet,G. Q. Zhang,Tauana Nagy,GS Sonke,Q. Sun,Marina Parton,Marco Colleoni,M. Schmidt,Adam Brufsky,Wajeeha Razaq,Bela Kaufman,D. Cameron,Carolyn Campbell,A. Tutt +75 more
TL;DR: The randomized OlympiA trial as discussed by the authors compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in BRCA1/2pv and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer.
261
Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
Juliane M. Jürgensmeier,H.-J. Schmoll,Jane Robertson,L Brooks,M Taboada,Shethah Morgan,David Wilson,Paulo M. Hoff +7 more
TL;DR: Baseline VEGF and CEA levels were treatment-independent prognostic biomarkers for PFS and OS in both the studies; low sVEGFR-2 was associated with a trend towards improved cediranib effect in HORIZON II.
VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
A. Tutt,James Garber,R. D. Gelber,Kelly-Anne Phillips,Andrea Eisen,Oskar T. Johannsson,PS Rastogi,Karen Y. Cui,Sa Im,Rinat Yerushalmi,Adam Brufsky,M Taboada,G. Rossi,Greg Yothers,C. Singer,Luis Fein,Niklas Loman,D. Cameron,Carolyn Campbell,CE Geyer +19 more
TL;DR: OlympiA as discussed by the authors is the first randomized clinical trial to test a PARP inhibitor as adjuvant therapy and showed that OL significantly improved the primary endpoint of invasive disease-free survival (IDFS) and secondary endpoint of distant DFS (DDFS) compared with placebo (PL).